ArticleExpert opinion on biological therapy2015
Biologics as countermeasures for acute radiation syndrome: where are we now?
Article in Expert opinion on biological therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Synthesis and Radioprotective Activity of Benzyl Sulfoxide/Sulfone Coumarins Derived from Ex-RAD.Molecules (Basel, Switzerland) · 2026Article
- Oxygen-enhanced assembloid-based vascularized intestinal-on-a-chip for radioprotective drug evaluation.Frontiers in toxicology · 2026Article
- Organs on chips: fundamentals, bioengineering and applications.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- Imidazolyl ethanamide pentandioic acid promotes hematopoietic recovery following sublethal radiation in a murine model.International journal of radiation biology · 2025Article
- Dietary methionine supplementation promotes mice hematopoiesis after irradiation.Military Medical Research · 2024Article
- Study of long-term effects of pelvic radiotherapy on the function of bone marrow in recurrent cervical cancer patients.International journal of medical sciences · 2024Article
- Construction, Features and Regulatory Aspects of Organ-chip for Drug Delivery Applications: Advances and Prospective.Current pharmaceutical design · 2024Review
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects.Antioxidants (Basel, Switzerland) · 2023Review
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation.Bioengineering (Basel, Switzerland) · 2022Review
- Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9.Cell death discovery · 2021Article
- Irradiation Haematopoiesis Recovery Orchestrated by IL-12/IL-12Rβ1/TYK2/STAT3-Initiated Osteogenic Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells.Frontiers in cell and developmental biology · 2021Article
- Article
- microRNA and Metabolite Signatures Linked to Early Consequences of Lethal Radiation.Scientific reports · 2020Article
- Organs-on-a-Chip Module: A Review from the Development and Applications Perspective.Micromachines · 2018Review
- Modeling radiation injury-induced cell death and countermeasure drug responses in a human Gut-on-a-Chip.Cell death & disease · 2018Article
- The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.Scientific reports · 2017Article
- Succinate ester derivative of δ-tocopherol enhances the protective effects againstScientific reports · 2017Article
- THE POTENTIATION OF THE RADIOPROTECTIVE EFFICACY OF TWO MEDICAL COUNTERMEASURES, GAMMA-TOCOTRIENOL AND AMIFOSTINE, BY A COMBINATION PROPHYLACTIC MODALITY.Radiation protection dosimetry · 2016Article
- Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.Expert opinion on therapeutic patents · 2016Review
- γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant scientific advances toward the development of a safe, nontoxic and effective radiation countermeasure for acute radiation syndrome (ARS) over the past six decades, no drug has been approved by the US FDA. Several biologics are currently under development as radiation countermeasures for ARS, of which three have received FDA Investigational New Drug (IND) status for clinical investigation. Presently, two of these agents, entolimod (CBLB502) and HemaMax (recombinant human IL-12) are progressing with large animal studies and clinical trials. Neupogen (G-CSF, filgrastim) has recently been recommended for approval by an FDA Advisory Committee. Filgrastim, GM-CSF (Leukine, sargramostim), and PEGylated G-CSF (Neulasta) have high potential and well-documented therapeutic effects in countering myelosuppression and may receive full licensing approval by the FDA in the future. The former two biologics are available in the US Strategic National Stockpile (SNS) for use in the event of nuclear or radiological emergency. The Emergency Use Authorization (EAU) application for entolimod may be filed soon with the FDA. Biologics are attractive agents that are progressing along the path for FDA approval, to fill the unmet need for ARS countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.